Cargando…

Pioglitazone could induce remission in major depression: a meta-analysis

BACKGROUND: Pioglitazone, a selective agonist of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ), prescribed for the treatment of type 2 diabetes, could have antidepressant properties. However, its potential to induce remission of major depressive episodes,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colle, Romain, de Larminat, Delphine, Rotenberg, Samuel, Hozer, Franz, Hardy, Patrick, Verstuyft, Céline, Fève, Bruno, Corruble, Emmanuelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182046/ https://www.ncbi.nlm.nih.gov/pubmed/28031713 http://dx.doi.org/10.2147/NDT.S121149

Ejemplares similares

Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response
por: Mesdom, Pierre, et al.
Publicado: (2020)

The MAOA rs979605 Genetic Polymorphism Is Differentially Associated with Clinical Improvement Following Antidepressant Treatment between Male and Female Depressed Patients
por: Chappell, Kenneth, et al.
Publicado: (2022)

Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case–control study
por: Ciocan, Dragos, et al.
Publicado: (2021)

Psychological distress among outpatient physicians in private practice linked to COVID-19 and related mental health during the second lockdown
por: Frajerman, Ariel, et al.
Publicado: (2022)

Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings
por: Voican, Cosmin Sebastian, et al.
Publicado: (2016)

Intra-nasal Esketamine Induced Psychotic Disorder in a Post Covid-19 Major Depressive Episode: a case report
por: Tang, Julie, et al.
Publicado: (2023)

The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients
por: Chappell, Kenneth, et al.
Publicado: (2022)

Peripheral tryptophan and serotonin and kynurenine pathways in major depression: A case-control study
por: Colle, R., et al.
Publicado: (2021)

The TRKB rs2289656 genetic polymorphism is associated with acute suicide attempts in depressed patients: A transversal case control study
por: Deflesselle, Eric, et al.
Publicado: (2018)

Astroglial Connexins Inactivation Increases Relapse of Depressive-like Phenotype after Antidepressant Withdrawal
por: Portal, Benjamin, et al.
Publicado: (2022)

Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later
por: Gasnier, Matthieu, et al.
Publicado: (2022)

Non-overweight depressed patients who respond to antidepressant treatment have a higher risk of later metabolic syndrome: findings from the METADAP cohort
por: El Asmar, K., et al.
Publicado: (2023)

Telemedicine use during the COVID-19 lockdown is associated with fewer depressive symptoms among physicians in private practice
por: Frajerman, Ariel, et al.
Publicado: (2023)

Hippocampal volume predicts antidepressant efficacy in depressed patients without incomplete hippocampal inversion
por: Colle, Romain, et al.
Publicado: (2016)

Early life adversity is associated with a smaller hippocampus in male but not female depressed in-patients: a case–control study
por: Colle, Romain, et al.
Publicado: (2017)

Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/Depression
por: Mendez-David, Indira, et al.
Publicado: (2017)

Psychiatric disorders and long COVID
por: Gasnier, Matthieu, et al.
Publicado: (2022)

128. Long Covid and Psychiatric Disorders 4 Months After a Hospitalization for COVID-19: A Cross Sectional Study
por: Gasnier, Matthieu, et al.
Publicado: (2023)

The human plasma-metabolome: Reference values in 800 French healthy volunteers; impact of cholesterol, gender and age
por: Trabado, Séverine, et al.
Publicado: (2017)

Santé mentale des médecins libéraux français pendant la deuxième vague de COVID 19
por: Frajerman, Ariel, et al.
Publicado: (2023)

quality of remission in the major depressive disorder
por: Chebli, H., et al.
Publicado: (2023)

The improved Clinical Global Impression Scale (iCGI): development and validation in depression
por: Kadouri, Alane, et al.
Publicado: (2007)

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study
por: Saragoussi, Delphine, et al.
Publicado: (2017)

Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review
por: Nguyen, Thi Mai Loan, et al.
Publicado: (2023)

Major Depressive Disorder and Oxidative Stress: A Review of Peripheral and Genetic Biomarkers According to Clinical Characteristics and Disease Stages
por: Ait Tayeb, Abd El Kader, et al.
Publicado: (2023)

Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
por: Jollant, Fabrice, et al.
Publicado: (2023)

P124. Which Patients Will Have Mental Disorders After Hospitalization for COVID-19?
por: Gasnier, Matthieu, et al.
Publicado: (2022)

Treatment strategies to improve and sustain remission in major depressive disorder
por: Madhukar H., Trivedi, et al.
Publicado: (2008)

Cognitive remission: a novel objective for the treatment of major depression?
por: Bortolato, Beatrice, et al.
Publicado: (2016)

How could stress lead to major depressive disorder?
por: Richter-Levin, Gal, et al.
Publicado: (2018)

Anosmia during acute COVID-19 and psychiatric outcomes 4 months later: Results from the prospective COMEBAC cohort
por: Faulet, Théo, et al.
Publicado: (2023)

Assessment of cerebrovascular reactivity during major depression and after remission of disease
por: Vakilian, Alireza, et al.
Publicado: (2010)

Excess cost of non-remission among outpatients with major depressive disorder
por: Woo, Jong-Min, et al.
Publicado: (2014)

Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder
por: Korgaonkar, Mayuresh S., et al.
Publicado: (2019)

Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
por: Choi, Hyebin, et al.
Publicado: (2021)

Report of depressive symptoms on waiting list and mortality after liver and kidney transplantation: a prospective cohort study
por: Corruble, Emmanuelle, et al.
Publicado: (2011)

Proteomic Analysis of Serum from Patients with Major Depressive Disorder to Compare Their Depressive and Remission Statuses
por: Lee, Jiyeong, et al.
Publicado: (2015)

Clinical validity of a population database definition of remission in patients with major depression
por: Sicras-Mainar, Antoni, et al.
Publicado: (2010)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
por: Mocking, Roel J. T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_krltm8pebav2seribdjugmjsmp